Amicus Therapeutics

Amicus Puts Positive Spin on Failure of its Phase III Trial for Pompe Disease
Amicus Puts Positive Spin on Failure of its Phase III Trial for Pompe Disease
BioSpace
Amicus Therapeutics
clinical trials
Pompe disease
AT-GAA
Flag link:
Amicus shares surge as Sanofi struggles to raise a cheer for mixed pivotal data for a PhIII contender — and analysts blow a raspberry
Amicus shares surge as Sanofi struggles to raise a cheer for mixed pivotal data for a PhIII contender — and analysts blow a raspberry
Endpoints
Sanofi
Amicus Therapeutics
clinical trials
Pompe disease
Avalglucosidase alfa
Lumizyme
Flag link:
Amicus shares early look at Batten disease gene therapy
Amicus shares early look at Batten disease gene therapy
Fierce Biotech
Amicus Therapeutics
Batten disease
gene therapy
AAV-CLN6
Flag link:
Thermo Fisher to manufacture gene therapies being developed by Amicus
Thermo Fisher to manufacture gene therapies being developed by Amicus
Fierce Pharma
Thermofisher
Amicus Therapeutics
gene therapy
CDMOs
Flag link:
Amicus widens UPenn gene therapy collaboration
Amicus widens UPenn gene therapy collaboration
Biopharma Dive
Amicus Therapeutics
UPenn
gene therapy
Galafold
Fabry disease
Flag link:
Amicus Announces Positive Results for AT-GAA in Pompe Disease
Amicus Therapeutics
AT-GAA
Pompe disease
Flag link:
Amicus Therapeutics Ramps Up Gene Therapy Portfolio with Acquisition of 10 Programs
Amicus Therapeutics Ramps Up Gene Therapy Portfolio with Acquisition of 10 Programs
CP Wire
Amicus Therapeutics
gene therapy
Batten disease
Flag link:
FDA kills off Amicus’ 2018 accelerated approval plan
FDA kills off Amicus’ 2018 accelerated approval plan
Fierce Biotech
FDA
Amicus Therapeutics
Pompe disease
AT-GAA
Flag link:
FDA Approves Eight Novel Drugs in August
FDA Approves Eight Novel Drugs in August
BioSpace
Kyowa Hakko Kirin
Poteligeo
Alnylam
Onpattro
Amicus Therapeutics
Galafold
TherapeuticMD
Annovera
Biocodex
Diacomit
Dompe Group
Oxervate
Shire
Takhzyro
Merck
Pifeltro
Flag link:
Amicus Finally Wins FDA Nod, Will Price Fabry Drug Below Rivals
Amicus Finally Wins FDA Nod, Will Price Fabry Drug Below Rivals
Xconomy
Fabry disease
FDA
Amicus Therapeutics
Galafold
Flag link:
2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs
2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs
TheStreet.com
biotech
M&A
Bluebird Bio
Amicus Therapeutics
Flag link:
Prescribed Reading: DMD, MS and other acronyms
Prescribed Reading: DMD, MS and other acronyms
Biopharma Dive
Celgene
Nimbus
Endocyte
Amicus Therapeutics
Catabasis
Motif Biosciences
Flag link:
Amicus’ latest positive update on Pompe drug hints at accelerated approval pitch
Amicus’ latest positive update on Pompe drug hints at accelerated approval pitch
Endpoints
Amicus Therapeutics
Pompe disease
ATB200/AT2221
Flag link:
The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter
The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter
Stat
biotech
Axovant Sciences
intepirdine
SAGE Therapeutics
brexanolone
AbbVie
risankizumab
Global Blood Therapeutics
GBT-440
DBV Technologies
Viaskin Peanut
Cytokinetics
Amicus Therapeutics
ATB200
Spark Therapeutics
Bluebird Bio
Revance Therapeutics
RT002
Flag link:
Signaling a major shift at the FDA, regulators put Amicus’ once-spurned drug on fast track
Signaling a major shift at the FDA, regulators put Amicus’ once-spurned drug on fast track
Endpoints
FDA
Amicus Therapeutics
migalastat
Fabry disease
fast track
Flag link:
FDA Reverses Decision, Allowing Amicus To File For Rare Disease Drug
FDA Reverses Decision, Allowing Amicus To File For Rare Disease Drug
Forbes
FDA
Amicus Therapeutics
Rare Diseases
Fabry disease
migalastat
Flag link:
Are These 2 Biotechs Diamonds in the Rough?
Are These 2 Biotechs Diamonds in the Rough?
Motley Fool
biotech
Amicus Therapeutics
Adamas Pharmaceuticals
ADS-5102
Galafold
Flag link:
Biotechs Breaking Out On Drug Development News
Biotechs Breaking Out On Drug Development News
Forbes
Bluebird Bio
Esperion Therapeutics
Amicus Therapeutics
Kite Pharma
Flag link:
Four biotech stocks surging on optimism about drug trials, product launches
Four biotech stocks surging on optimism about drug trials, product launches
Marketwatch
clinical trials
Bluebird Bio
Amicus Therapeutics
Kite Pharma
NeuroDerm
Flag link:
4 Biopharma Stocks Moving the Market on Wednesday
4 Biopharma Stocks Moving the Market on Wednesday
Yahoo/24-7 Wall St
Skyline Medical
Dynavax Technologies
Amicus Therapeutics
Pacira
Flag link:

Pages